Torsten Liersch

Robert Koch Str. 40
Goettingen, NI 37075, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 45 publications

Unrecognized mutations in DPYD* 2 A wild-type rectal cancer patients receiving postoperative 5-FU-based chemotherapy - do they have a clinical impact?

Unrecognized mutations in DPYD* 2 A wild-type rectal cancer patients receiving postoperative 5-FU-based chemotherapy - do they have a clinical impact?

Journal: Cancer chemotherapy and pharmacology

Published: January 26, 2025

Incomplete DPYD haplotype B3 in a patient with locally advanced gastric cancer: Reconsidering the 5-FU dosage strategy.

Incomplete DPYD haplotype B3 in a patient with locally advanced gastric cancer: Reconsidering the 5-FU dosage strategy.

Journal: European journal of cancer (Oxford, England : 1990)

Published: April 10, 2024

Cytogenetic signatures favoring metastatic organotropism in colorectal cancer.

Cytogenetic signatures favoring metastatic organotropism in colorectal cancer.

Journal: Nature communications

Published: December 28, 2022

Evolutionary patterns of chromosomal instability and mismatch repair deficiency in proximal and distal colorectal cancer.

Evolutionary patterns of chromosomal instability and mismatch repair deficiency in proximal and distal colorectal cancer.

Journal: Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland

Published: January 31, 2021

Quality of life in rectal cancer patients with or without oxaliplatin in the randomised CAO/ARO/AIO-04 phase 3 trial.

Quality of life in rectal cancer patients with or without oxaliplatin in the randomised CAO/ARO/AIO-04 phase 3 trial.

Journal: European journal of cancer (Oxford, England : 1990)

Published: August 24, 2020

Prognostic value of the micronucleus assay for clinical endpoints in neoadjuvant radiochemotherapy for rectal cancer.

Prognostic value of the micronucleus assay for clinical endpoints in neoadjuvant radiochemotherapy for rectal cancer.

Journal: BMC cancer

Published: June 11, 2020

CONKO-006: A randomised double-blinded phase IIb-study of additive therapy with gemcitabine + sorafenib/placebo in patients with R1 resection of pancreatic cancer - Final results.

CONKO-006: A randomised double-blinded phase IIb-study of additive therapy with gemcitabine + sorafenib/placebo in patients with R1 resection of pancreatic cancer - Final results.

Journal: European journal of cancer (Oxford, England : 1990)

Published: March 20, 2020

Combined targeting of HER-2 and HER-3 represents a promising therapeutic strategy in colorectal cancer.

Combined targeting of HER-2 and HER-3 represents a promising therapeutic strategy in colorectal cancer.

Journal: BMC cancer

Published: February 22, 2019

Leukocytosis and neutrophilia as independent prognostic immunological biomarkers for clinical outcome in the CAO/ARO/AIO-04 randomized phase 3 rectal cancer trial.

Leukocytosis and neutrophilia as independent prognostic immunological biomarkers for clinical outcome in the CAO/ARO/AIO-04 randomized phase 3 rectal cancer trial.

Journal: International journal of cancer

Published: February 15, 2019

Association of Plane of Total Mesorectal Excision With Prognosis of Rectal Cancer: Secondary Analysis of the CAO/ARO/AIO-04 Phase 3 Randomized Clinical Trial.

Association of Plane of Total Mesorectal Excision With Prognosis of Rectal Cancer: Secondary Analysis of the CAO/ARO/AIO-04 Phase 3 Randomized Clinical Trial.

Journal: JAMA surgery

Published: June 07, 2018

Impact of age on the efficacy of oxaliplatin in the preoperative chemoradiotherapy and adjuvant chemotherapy of rectal cancer: a post hoc analysis of the CAO/ARO/AIO-04 phase III trial.

Impact of age on the efficacy of oxaliplatin in the preoperative chemoradiotherapy and adjuvant chemotherapy of rectal cancer: a post hoc analysis of the CAO/ARO/AIO-04 phase III trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: June 07, 2018

Neoadjuvant rectal score as individual-level surrogate for disease-free survival in rectal cancer in the CAO/ARO/AIO-04 randomized phase III trial.

Neoadjuvant rectal score as individual-level surrogate for disease-free survival in rectal cancer in the CAO/ARO/AIO-04 randomized phase III trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: May 03, 2018

Showing 1-12 of 45

Last Updated: 09/26/2026